Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.38%
0%
15.38%
6 Months
-6.9%
0%
-6.9%
1 Year
-3.57%
0%
-3.57%
2 Years
-62.5%
0%
-62.5%
3 Years
-92.29%
0%
-92.29%
4 Years
-98.95%
0%
-98.95%
5 Years
-98.62%
0%
-98.62%
Renalytix Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-22.66%
EBIT Growth (5y)
26.50%
EBIT to Interest (avg)
-28.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.04
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.22%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-29.09
EV to EBIT
-1.94
EV to EBITDA
-1.96
EV to Capital Employed
-13.76
EV to Sales
16.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ
Dec'24
Sep'24
Change(%)
Net Sales
0.60
0.40
50.00%
Operating Profit (PBDIT) excl Other Income
-3.40
-3.10
-9.68%
Interest
0.00
0.00
Exceptional Items
0.00
-0.50
100.00%
Consolidate Net Profit
-3.00
-3.60
16.67%
Operating Profit Margin (Excl OI)
-5,976.70%
-7,839.10%
186.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2024 is 50.00% vs -20.00% in Sep 2024
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2024 is 16.67% vs 35.71% in Sep 2024
Annual Results Snapshot (Consolidated) - Jun'24
Jun'24
Jun'23
Change(%)
Net Sales
1.80
2.80
-35.71%
Operating Profit (PBDIT) excl Other Income
-22.70
-34.70
34.58%
Interest
0.00
0.00
Exceptional Items
-4.00
-3.60
-11.11%
Consolidate Net Profit
-26.60
-37.90
29.82%
Operating Profit Margin (Excl OI)
-12,619.00%
-12,407.00%
-21.20%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2024 is -35.71% vs 27.27% in Jun 2023
Consolidated Net Profit
YoY Growth in year ended Jun 2024 is 29.82% vs -11.14% in Jun 2023
About Renalytix Plc 
Renalytix Plc
Software Products
Renalytix AI plc is an artificial intelligence-enabled in vitro diagnostics company. The Company’s diagnostic platform, KidneyIntelX, employs artificial intelligence-enabled algorithm that combines data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record (HER) systems, to generate a patient risk score. Its patient risk score enables prediction of progressive kidney function decline in chronic kidney disease (CKD), allowing physicians and healthcare systems to manage the allocation of treatments and clinical resources to patients. KidneyIntelX provides a reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to manage patient treatment and compliance outcomes. The KidneyIntelX risk score is tied to specific clinical guideline recommendations developed by the healthcare system, health insurance providers or practice groups.
Company Coordinates 
Company Details
Avon Hse, 19 Stanwell Road , PENARTH None : CF64 2EZ
Registrar Details






